Clinical Trials Sponsored by Celsee Diagnostics

Total 2566 results

Celgene

Completed

An Observational Study to Assess Safety and Outcome of the Various Medication Usage Patterns in Clinical Routine Practice in Patients Receiving Lenalidomide. (REVIEW)

Multiple Myeloma
Celgene

Completed

Pharmacogenetics Sampling of the CC-90007-CP-003 Study Cohort

Hepatic Insufficiency

United States
Celgene

Completed

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Melanoma | Sarcoma | Neoplasms | Lymphoma | Renal Cell Carcinoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Leukemia | Breast Cancer | Small Cell Lung Cancer | Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Non-Small Cell Lung Cancer | Osteosarcoma | Glioblastoma Multiforme | Metastatic Breast... and other conditions

United States
Celgene

Completed

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Chronic Lymphocytic Leukemia

United States
Celgene

Completed

Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects

Healthy Volunteer

United States
Celgene

Completed

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects

Healthy Volunteer

United States
Celgene

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy Subjects

Healthy Volunteer

United States
Celgene

Completed

Bioavailability of Enasidenib (CC-90007) Sprinkle Formulation Relative to the Reference Tablet Formulation and Effect of Food on the Pharmacokinetics of Sprinkle Formulation in Healthy Adults

Healthy Volunteers

United States
Celgene

Completed

ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Celgene

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of CC-99677 in Healthy Adult Subjects

Healthy Volunteer

United Kingdom
Celgene

Completed

Longterm Follow-up of Subjects Treated With bb2121

Multiple Myeloma

United States
Celgene

Completed

A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid

United States, Canada
Celgene

Completed

Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Leukemia Lymphocytic Chronic B-Cell

United States, Austria
Celgene

Completed

A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.

Leukemia, Myeloid, Acute

Germany, Netherlands, Denmark
Celgene

Terminated

A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States
Celgene

Terminated

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

Stage IV (Metastatic) Breast Cancer

United States
Celgene

Completed

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Celgene

Terminated

Trial of Romidepsin and Bortezomib for Multiple Myeloma

Multiple Myeloma

United States
Celgene

Completed

Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer

Metastatic Breast Cancer

Ukraine
Celgene

Completed

A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma

Multiple Myeloma

Japan
Celgene

Completed

Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003

Myelodysplastic Syndrome

United States, Germany
Celgene

Terminated

A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus

Discoid Lupus

United States
Celgene

Completed

Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea

Myelodysplastic Syndrome

Korea, Republic of
Celgene

Completed

A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan

Multiple Myeloma

Taiwan
Celgene

Terminated

Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis

Healthy Volunteers | Parapsoriasis

United States
Celgene

Completed

MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry (MORE)

Myelodysplastic Syndrome

Italy
Celgene

Completed

An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

Italy, United Kingdom, Germany, Australia, Bulgaria, France, Greece, Hungary, Netherlands, Poland, Spain
Celgene

Completed

2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects

Healthy

United States
Celgene

Completed

A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

Japan
Celgene

Completed

Study to Evaluate Pharmacokinetics of Pomalidomide in Hepatically Impaired Males

Clinical Pharmacology, Healthy Volunteer Study

United States
Celgene

Completed

An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin

Non-Small Cell Lung Cancer (NSCLC)

Russian Federation
Celgene

Completed

Study to Evaluate Pharmacokinetics of Single Oral Doses of Formulated and Non-Formulated CC-122, and Food Effect Study

Clinical Pharmacology, Healthy Male Volunteer Study

United States
Celgene

Completed

A Phase 1 QT Study in Healthy Male Subjects (QT/QTc)

Clinical Pharmacology, Healthy Volunteer Study

United States
Celgene

Completed

Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease (SCD-001)

Anemia, Sickle Cell

United States
Celgene

Completed

A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Leukemia, B-Cell, Chronic

Canada, United States, Germany, Italy, Spain, Sweden, United Kingdom
Celgene

Completed

Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension

Healthy Volunteers

United States
Celgene

Completed

Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Celgene

Completed

Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292

Healthy

United States
Celgene

Completed

A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.

Pancreatic Cancer

United States, Canada, Spain, Australia, France, Germany, Austria, Italy, Ukraine
Celgene

Completed

Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Carcinoma, Squamous Cell of Head and Neck

United States
Celgene

Terminated

A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab

Squamous Cell Carcinoma of the Head and Neck

United States
Celgene

No longer available

Expanded Access for AG-221

Acute Myeloid Leukemia

United States
Celgene

Completed

Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma

Multiple Myeloma

France, Belgium
Celgene

Terminated

A Study to Assess Clinical an Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Route Clinical Practice Treating Pancreatic Cancer (TRUST)

Pancreatic Neoplasms

Netherlands
Celgene

Terminated

Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease

Crohn Disease

United States, Korea, Republic of, Netherlands, Spain, Belgium, Denmark, Australia, Austria, Russian Federation, United Kingdom, Croatia, Canada, Italy, Hungary, Israel, Portugal, Serbia, Poland, Germany, France, Czechia, Greece, Sl... and more
Celgene

Completed

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence (RESUME)

Primary Myelofibrosis | MPN-associated Myelofibrosis

United States, Netherlands, France, Australia, Italy, United Kingdom, Canada, Germany, China, Spain, Belgium, Austria, Poland, Sweden, Japan, Russian Federation
Celgene

Completed

Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial) (ORIGIN)

B-Cell Chronic Lymphocytic Leukemia

United States, Spain, Australia, Belgium, Italy, Serbia, Poland, Israel, New Zealand, Portugal, Brazil, France, Bulgaria, Croatia, Czechia, Hungary, Russian Federation, Netherlands, Romania, Denmark, United Kingdom, Austria, Canada, South... and more
Celgene

Completed

Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

China
Celgene

Completed

A Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in Spain (RETRO)

Multiple Myeloma

Spain
Celgene

Completed

A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease

Crohn Disease

United States, Australia, Canada, Slovakia, Hungary

3

Subscribe